Nilotinib efficacy in a patient resistant to imatinib
Imatinib, a BCR-ABL inhibitor, is the standard of care for the first-line treatment of patients with chronic-phase CML. Despite the optimal results, some patients develop resistance to imatinib. For these patients, the second-generation tyrosine kinase inhibitors represent effective therapeutic opti...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SEEd
2015-10-01
|
| coleção: | Clinical Management Issues |
| Assuntos: | |
| Acesso em linha: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1093 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|